ATE110113T1 - Kristallines r-h-gm-csf und verfahren zur herstellung. - Google Patents

Kristallines r-h-gm-csf und verfahren zur herstellung.

Info

Publication number
ATE110113T1
ATE110113T1 AT90306042T AT90306042T ATE110113T1 AT E110113 T1 ATE110113 T1 AT E110113T1 AT 90306042 T AT90306042 T AT 90306042T AT 90306042 T AT90306042 T AT 90306042T AT E110113 T1 ATE110113 T1 AT E110113T1
Authority
AT
Austria
Prior art keywords
csf
crystalline
production
preparing
molecular weight
Prior art date
Application number
AT90306042T
Other languages
English (en)
Inventor
Paul Reichert
Gerald S Hammond
Hung V Le
Tattanahali L Nagabhushan
Paul P Trotta
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE110113T1 publication Critical patent/ATE110113T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/145—Colony stimulating factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90306042T 1989-06-06 1990-06-04 Kristallines r-h-gm-csf und verfahren zur herstellung. ATE110113T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/362,187 US5109119A (en) 1989-06-06 1989-06-06 Crystalline r-h-gm-csf and method

Publications (1)

Publication Number Publication Date
ATE110113T1 true ATE110113T1 (de) 1994-09-15

Family

ID=23425041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90306042T ATE110113T1 (de) 1989-06-06 1990-06-04 Kristallines r-h-gm-csf und verfahren zur herstellung.

Country Status (14)

Country Link
US (2) US5109119A (de)
EP (3) EP0561429A1 (de)
JP (1) JP2572160B2 (de)
KR (1) KR960004454B1 (de)
AT (1) ATE110113T1 (de)
AU (1) AU644083B2 (de)
CA (1) CA2058441C (de)
DE (1) DE69011586T2 (de)
DK (1) DK0402070T3 (de)
FI (1) FI915709A0 (de)
HK (1) HK184996A (de)
HU (1) HU209871B (de)
NO (1) NO914771L (de)
WO (1) WO1990015151A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486572B1 (de) * 1989-08-11 1998-01-07 Amrad Corporation Limited Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate
EP0668914B1 (de) 1992-06-09 2000-08-16 Chiron Corporation Kristallisierung von m-csf
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
PE20020394A1 (es) * 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
EP1425304B9 (de) * 2001-07-11 2010-09-08 Maxygen, Inc. G-csf konjugate
US7765302B2 (en) * 2003-06-30 2010-07-27 Nortel Networks Limited Distributed call server supporting communication sessions in a communication system and method
CN101031323A (zh) * 2004-07-16 2007-09-05 尼克塔治疗亚拉巴马公司 Gm－csf部分与聚合物的缀合物
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
WO2007102946A2 (en) * 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
EP3079668A1 (de) 2013-12-09 2016-10-19 Durect Corporation Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
JP3038348B2 (ja) * 1984-11-20 2000-05-08 シェーリング コーポレイション ヒト顆粒状、マクロファージおよび好酸球の細胞増殖因子活性を示すポリペプチドをコードするｃＤＮＡクローン
JP2595216B2 (ja) * 1986-12-12 1997-04-02 日清製粉株式会社 α―アミラーゼインヒビターの結晶の製造方法
US4912200A (en) * 1987-05-11 1990-03-27 Schering Corporation Extraction of granulocyte macrophage colony stimulating factor from bacteria
WO1989012092A1 (en) * 1988-05-31 1989-12-14 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts

Also Published As

Publication number Publication date
HK184996A (en) 1996-10-11
HUT58822A (en) 1992-03-30
DE69011586T2 (de) 1995-03-02
JP2572160B2 (ja) 1997-01-16
EP0476022A1 (de) 1992-03-25
DE69011586D1 (de) 1994-09-22
CA2058441C (en) 1997-12-16
CA2058441A1 (en) 1990-12-07
EP0561429A1 (de) 1993-09-22
EP0402070B1 (de) 1994-08-17
FI915709A7 (fi) 1991-12-04
FI915709A0 (fi) 1991-12-04
JPH04502014A (ja) 1992-04-09
KR920700293A (ko) 1992-02-19
EP0402070A1 (de) 1990-12-12
HU209871B (en) 1994-11-28
US5616555A (en) 1997-04-01
AU644083B2 (en) 1993-12-02
NO914771D0 (no) 1991-12-04
WO1990015151A1 (en) 1990-12-13
HU904835D0 (en) 1992-02-28
KR960004454B1 (ko) 1996-04-06
DK0402070T3 (da) 1994-09-12
US5109119A (en) 1992-04-28
NO914771L (no) 1991-12-04
AU5834890A (en) 1991-01-07

Similar Documents

Publication Publication Date Title
ATE110113T1 (de) Kristallines r-h-gm-csf und verfahren zur herstellung.
DE68922726D1 (de) Medizinisches material und verfahren zur herstellung.
PT81168A (de) Blutgerinnungshemmende proteine verfahren zur herstellung sowiederen verwendung
DE69125035D1 (de) Verfahren zur herstellung von interferon-alpha-2 kristallen
ATE108067T1 (de) Impfstoff und verfahren zur herstellung.
DE59107966D1 (de) Hohlnadel zur medizinischen verwendung und verfahren zur herstellung derartiger hohlnadeln
DE68928482D1 (de) Verfahren zur Herstellung eines Bipolartransistors
DE69217198D1 (de) Saugnapf und verfahren zur herstellung desselben
DE69133492D1 (de) Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
ATE71658T1 (de) Verfahren zur herstellung von humanlysozym.
DE69427955D1 (de) Verfahren zur Herstellung von 2,2-Difluorketensilylacetalen und alpha,alpha-Difluor-beta -Silyloxy-1,3-Dioxolan-4-Propansäureestern
IT1223099B (it) Procedimento per l'iniettofusione di materie artificiali termoplastiche
DE69318909D1 (de) Verfahren zur Herstellung von menschlichem Wachstumshormon
DE3784518D1 (de) Medizinisches material und verfahren zur herstellung.
ATA293786A (de) Mischung zur herstellung von formkoerpern sowie deren verwendung und daraus gebildete formkoerper
ATA909285A (de) Verfahren zur herstellung von hautpflegenden kompositionen mit keratolytischer und entzuendungshemmender wirkung
ATA163789A (de) Verfahren zur herstellung von keramischen formteilen
AT389514B (de) Verfahren zur herstellung von neuen purinderivaten und ihren salzen
DE3879063D1 (de) Keramikbasis sowie verfahren zur herstellung.
DE68928787D1 (de) Verfahren zur Herstellung eines Bipolartransistors
DE3586940D1 (de) Polypeptid und dessen verfahren zur herstellung.
ATA327685A (de) Verfahren zur herstellung eines neuen lymphokins (lk 2) sowie verwendung von lk 2 zur herstellung eines pharmazeutischen praeparates
DE69115325D1 (de) Rekombinantes Plasmid für die Expression von Lipase und Verfahren zur Herstellung von Lipase
AT397723B (de) Verfahren zur herstellung radiokonjugierter polymerer und verwendung derselben
DE3787765D1 (de) Antibiotika "Mureidomycine A,B,C und D" genannt, deren Verfahren zur Herstellung und deren Verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee